Stockscreener 앱 받기
0.85
2.62%
-0.0229
시간 외 거래:
.86
0.01
+1.18%
전일 마감가:
$0.8729
열려 있는:
$0.87
하루 거래량:
846.25K
Relative Volume:
0.73
시가총액:
$98.71M
수익:
-
순이익/손실:
$-21.32M
주가수익비율:
-3.7862
EPS:
-0.2245
순현금흐름:
$-19.96M
1주 성능:
-4.48%
1개월 성능:
-22.73%
6개월 성능:
-18.27%
1년 성능:
+69.90%
1일 변동 폭
$0.8418
$0.8701
1주일 범위
$0.8418
$0.92
52주 변동 폭
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
명칭
Oncolytics Biotech Inc
전화
(403) 670-7377
주소
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.85 | 101.37M | 0 | -21.32M | -19.96M | -0.2245 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Inc.Common Stock (NQ: ONCY - FinancialContent
Oncolytics Biotech stock (CA6823101073): Q1 loss deepens and going concern warning puts focus on cas - AD HOC NEWS
Oncolytics Biotech (ONCY) doubles Q1 loss and warns on going concern - Stock Titan
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
Oncolytics Biotech stock (CA6823101073): Q4 earnings miss and upcoming report - AD HOC NEWS
TradingKey - TradingKey
Oncolytics Biotech (ONCY) Eps Diluted (TTM) - Zacks Investment Research
Lobbying Update: $35,000 of ONCOLYTICS BIOTECH INC. lobbying was just disclosed - Quiver Quantitative
ONCY: Oncolytics BiotechInteractive Chart - Zacks Investment Research
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks - MSN
Oncolytics Biotech’s Pelareorep Data Reshapes Colorectal Cancer And Investor Outlook - Sahm
Oncolytics Biotech Reports Data in Colorectal Cancer Study - IPO Edge
Oncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum - Quantisnow
Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer, Pursues Accelerated FDA Approval for Pelareorep Therapy 7 - Minichart
Oncolytics Says Colorectal Cancer Drug Outperforms BenchmarksOncolytics Biotech (NASDAQ:ONCY) - Benzinga
Stocks In Play - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech Highlights Strong Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC - TradingView
Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer - TradingView
A colorectal cancer study hit 19.5-month response duration as FDA talks start - Stock Titan
Durable mCRC responses spur FDA talks for Oncolytics Biotech (NASDAQ: ONCY) - Stock Titan
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer - Yahoo Finance
CEO Chat with Jared Kelly, CEO of Oncolytics Biotech - Zacks Small Cap Research
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (ONCY) and Agilon Health (AGL) - The Globe and Mail
Lake Street Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oncolytics aligns with FDA on pivotal trial design for anal cancer By Investing.com - Investing.com South Africa
Oncolytics aligns with FDA on pivotal trial design for anal cancer - Investing.com UK
Oncolytics Biotech Aligns With FDA on Study Design for Pelareorep in Anal Cancer - marketscreener.com
Oncolytics (ONCY) Secures FDA Agreement on Pivotal Study Design - GuruFocus
Oncolytics Biotech Inc announces alignment with FDA on pivotal anal cancer study - marketscreener.com
Oncolytics Biotech Aligns with FDA on Pelareorep Trial - TipRanks
Oncolytics Biotech Aligns with FDA on Pivotal Study for Anal Cancer Immunotherapy Approval - Minichart
Oncolytics surges on FDA alignment for pivotal cancer trial By Investing.com - Investing.com India
Oncolytics Biotech | 8-K: Current report - Moomoo
Oncolytics surges on FDA alignment for pivotal cancer trial - Investing.com
Oncolytics aligns with FDA on randomized pivotal anal cancer trial for pelareorep - TradingView
Oncolytics Biotech (Nasdaq: ONCY) secures FDA alignment on pivotal anal cancer study design - Stock Titan
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study - ChartMill
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths (NASDAQ:ONCY) - Seeking Alpha
ONCY (Oncolytics Biotech Inc. Common Shares) posts wider Q3 2025 loss than consensus estimates, shares rise 5.66 percent.Social Investment Platform - Xã Thanh Hà
ONCY Should I Buy - Intellectia AI
Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst - MarketBeat
Published on: 2026-04-14 02:49:57 - baoquankhu1.vn
Equities Analysts Issue Forecasts for ONCY Q1 Earnings - MarketBeat
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oncolytics Biotech Inc 주식 (ONCY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.71%
자본화:
|
볼륨(24시간):